Does the EU's electronic package leaflet (ePI) change wrong-word risk?
Not by itself. Electronic product information (ePI) is the EU's approved product information in an electronic format, and the EU's own key principles say it doesn't change the content. So a correctly spelled wrong word in the approved text carries straight into the ePI, the same failure ContextRx documents on FDA DailyMed labels.
ContextRx doesn't study EU leaflets. The review habit carries over.
This page is general information, not legal or regulatory advice.
What ePI is
EMA describes ePI as the authorised, statutory product information for medicines, including the summary of product characteristics (SmPC), the package leaflet and the labelling, adapted for handling in electronic format and for sharing via the web, e-platforms and in print.
EMA's guidance for applicants says ePI covers Annex I (the SmPC), Annex II, Annex IIIA (labelling) and Annex IIIB (the package leaflet). For centrally authorised medicines, submitting ePI is voluntary until the new EU pharmaceutical legislation fully applies. It's created in EMA's PLM portal, and the usual Word and PDF product information annexes are still required.
The timeline, as EMA describes it
As of October 2026, EMA's ePI implementation roadmap is marked as a draft. It shows a phased, voluntary go-live for centrally authorised products, with the 2027 steps marked "to be confirmed":
- Q4 2026: go-live of voluntary submission for vaccines
- H1 2027 (to be confirmed): voluntary go-live for oncology products
- H2 2027 (to be confirmed): voluntary go-live for all centrally authorised products
The roadmap says initial implementation is in English, with all languages optional and fully multilingual at a later stage. EMA's guidance for applicants says submission in all languages is expected to become mandatory in future. Because the roadmap is a draft, dates can move. We'll update this page at the same address when they do.
What ePI doesn't change
The joint EMA, HMA and European Commission key principles say the development of ePI does not change the content of the product information: the information, headings, text or formatting. They also say generating ePI doesn't involve any change to that content.
EMA's guidance for applicants is stricter still about matching. When ePI is created outside a regulatory procedure, its content must be identical to the latest approved product information.
Our view: that's good for consistency and neutral for accuracy. ePI is only as accurate as the approved words.
Where wrong words come in
EMA's guidance for applicants says that once an ePI is published, the applicant is responsible for ensuring that, through each later procedure, the ePI is aligned with the latest approved product information. Any translations must also be aligned with the English ePI.
In our view, that creates moments where a fluent wrong word can slip in:
- carrying approved text into the new structured format
- updating the ePI after each variation
- adding translations later
Made-up example: a warning that should say "hypotension" is retyped during an update as "hypertension". Both are real words, and spellcheck passes both.
What to read for
Practice advice:
- After each variation, read the ePI against the approved product information for meaning, not just for format.
- Start with dosing, warnings and any line that tells the reader not to do something.
- Check that the ePI matches the QRD template version the approved text uses. See EU QRD templates and exact wording.
- If you're also testing the leaflet with readers, see readability user testing and wrong words.
- For why a side-by-side comparison can miss a wrong word that was already in the master, see compare-to-master vs read-for-meaning.
The US has its own structured electronic labels. See DailyMed SPL errors explained. For patient-facing US documents, see Medication Guide and IFU errors.
Sources
- EMA: ePI implementation roadmap (draft)
- EMA: Electronic product information (ePI)
- EMA: Electronic product information (ePI) submission during centralised procedures
- EMA: Electronic product information for human medicines in the EU: key principles
Last reviewed: October 14, 2026
More on contextual errors in FDA DailyMed labels.
Questions about wording on your own labels? Talk to us.
We scan freshly published FDA DailyMed labels every day and pull out these high-stakes wrong words.
Every Tuesday and Friday, a new case like this lands in your inbox if you subscribe.
FAQ
What is ePI in the EU?
It's the approved product information (SmPC, package leaflet and labelling) adapted to an electronic format that can be shared on the web, on e-platforms and in print.
When does EU ePI go live?
As of October 2026, EMA's draft roadmap shows voluntary submission for vaccines going live in Q4 2026, with voluntary go-live for oncology products in H1 2027 and for all centrally authorised products in H2 2027, both marked to be confirmed. Dates can change, so check EMA's latest roadmap.
Does ePI change the wording of the package leaflet?
No. The EU's key principles say ePI does not change the content of the product information. A wrong word in the approved text carries over.
How do I make sure ePI stays aligned with the approved product information?
EMA says the applicant must ensure the ePI is aligned with the latest approved product information through each later procedure. Practice advice: read it for meaning after each variation.
Does ContextRx study EU leaflets?
No. ContextRx cases come from US FDA DailyMed labels; the review habits carry over.